A Phase 2 interventional study of Lanifibranor and Placebo in NASH - Nonalcoholic Steatohepatitis and Diabetes Mellitus, Type 2, sponsored by Inventiva Pharma. Completed at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Inventiva Pharma · Phase 2, Interventional, and Treatment
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 324 are open to participants now.
This study's enrollment of 39 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Browse Non-alcoholic Fatty Liver Disease studies →Inventiva Pharma is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Liver-related:
Abnormal liver function as defined by central laboratory evaluation:
Albumin \< LLN ≥ 1.3 (unless patient is on anticoagulants) Total level ≥ 1.5 mg/dL (25.7 µmol/L) (patients with a documented history of Gilbert's syndrome can be enrolled if direct bilirubin is ≤ 0.45 mg/dL (7.7 μmol/L) )
Administration of drugs known to produce hepatic steatosis in the 6 months prior to Screening.
Diabetes related:
Patients on metformin, DPP-IVi, thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels, unless on stable doses in last 3 months
Obesity related:
Cardiovascular related:
21. History of or current unstable cardiac dysrhythmias 22. Unstable heart failure 23. Uncontrolled hypertension 24. Stroke or
General safety:
25. Significant systemic or major illnesses other than liver disease and pulmonary disease, organ transplantation, serious psychiatric disease, that, in the opinion of the investigator, would preclude treatment with lanifibranor and/or adequate follow up 26. Renal impairment measured as estimated (eGFR) value \< 60 mL/min 27. Concomitant treatment with PPAR-⍺ agonists (fibrates) 28. Patients on Vitamin E at doses ≥ 400 IU/day; doses of ≥ 400 IU/day are allowed when no qualitative change in dose for 6 months prior to Screening 29. Have a known to any of the IMPs 30. Previous exposure to lanifibranor or empagliflozin 31. Present pregnancy/lactation 32. Metallic implant of any sort that prevents MRI examination 33. Participation in any clinical trial of an approved or non approved medicinal product/device within 3 months from Screening or five half-lives of the investigational drug from Screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each, once-a-day (QD) with food. For oral use. QD for 24 weeks.
Drug: Lanifibranor
Two lanifibranor placebo-matching tablets once-a-day (QD) with food. For oral use. QD for 24 weeks.
Drug: Placebo
Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each plus one empagliflozin film-coated tablet of 10 mg (10mg/day), once-a-day (QD) with food. For oral use. QD for 24 weeks
Drug: Lanifibranor · Drug: Empagliflozin
800 mg
Placebo to match
10 mg
Also known as: Jardiance
Absolute Change in HbA1c
Effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24
Time frame: From Baseline to Week 24
Change in Liver Tests (ALT)
Defined as Absolute Change from Baseline
Time frame: from Baseline to Week 24
Change in Liver Tests (AST)
Defined as Absolute Change from Baseline
Time frame: from Baseline to Week 24
Percentage Change in Insulin Resistance and Glycaemic Control (HOMA-IR)
HOMA-IR : The homeostatic model assessment for insulin resistance (HOMA-IR) is a method used to quantify insulin resistance, and was derived by the central laboratory from glucose and insulin values using the formula (Fasting glucose mg/dL x fasting insulin µIU/mL) / 405. Lower values are considered better outcome.
Time frame: from Baseline to Week 24
Change in Insulin Resistance and Glycaemic Control (Insulin)
Defined as Relative Change from Baseline
Time frame: from Baseline to Week 24
Change in Insulin Resistance and Glycaemic Control (Adiponectin)
Defined as Fold Change from Baseline
Time frame: from Baseline to Week 24
Change in Lipid Parameters (HDL Cholesterol)
Defined as Relative Change
Time frame: from Baseline to Week 24
Change in Body Weight and Body Composition (Body Weight)
Defined as Relative Change from Baseline
Time frame: from Baseline to Week 24
Change in Body Weight and Body Composition (VAT/SAT Ratio)
Ratio VAT / SAT - Results for Relative Change from Baseline VAT : MRI L3 visceral adipose tissue SAT : MRI L3 subcutaneous adipose tissue
Time frame: from Baseline to Week 24
Recruitment of patients started in June 2022 and last patient was recruited in November 2023. A total of 213 patients were screened for the study.
| Milestone | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Started | 12 | 13 | 14 |
| Completed | 12 | 12 | 9 |
| Not completed | 0 | 1 | 5 |
| Withdrew: Non compliance with study drug | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24
| percentage of glycosylated hemoglobin | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Absolute Change in HbA1c | -1.11 (-1.6 to -0.62) | -1.54 (-2.02 to -1.06) | 0.16 (-0.32 to 0.63) |
Defined as Absolute Change from Baseline
| Absolute Change (U/L) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Liver Tests (ALT) | -26.60 (-38.08 to -15.12) | -29.63 (-42.13 to -17.13) | -5.65 (-17.89 to 6.59) |
Defined as Absolute Change from Baseline
| Absolute Change (U/L) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Liver Tests (AST) | -13.67 (-20.66 to -6.68) | -17.81 (-25.5 to -10.12) | 1.3 (-6.11 to 8.71) |
HOMA-IR : The homeostatic model assessment for insulin resistance (HOMA-IR) is a method used to quantify insulin resistance, and was derived by the central laboratory from glucose and insulin values using the formula (Fasting glucose mg/dL x fasting insulin µIU/mL) / 405. Lower values are considered better outcome.
| Percentage change | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Percentage Change in Insulin Resistance and Glycaemic Control (HOMA-IR) | -50.79 (-95.69 to -5.89) | -45.23 (-89.86 to -0.61) | 35.01 (-10.29 to 80.32) |
Defined as Relative Change from Baseline
| Percentage Change | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Insulin Resistance and Glycaemic Control (Insulin) | -33.48 (-68.24 to 1.28) | -38.16 (-72.16 to -4.16) | 10.17 (-23.63 to 43.96) |
Defined as Fold Change from Baseline
| Fold Change | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Insulin Resistance and Glycaemic Control (Adiponectin) | 2.87 (2.05 to 3.68) | 3.03 (2.18 to 3.89) | 1.24 (0.39 to 2.09) |
Defined as Relative Change
| Relative Change (%) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Lipid Parameters (HDL Cholesterol) | 16.48 (5.24 to 27.72) | 15.30 (3.04 to 27.56) | 2.55 (-9.76 to 14.86) |
Defined as Relative Change from Baseline
| Relative Change (%) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Body Weight and Body Composition (Body Weight) | 3.6 (2 to 5.19) | 0.25 (-1.50 to 2.01) | -1.16 (-2.84 to 0.53) |
Ratio VAT / SAT - Results for Relative Change from Baseline VAT : MRI L3 visceral adipose tissue SAT : MRI L3 subcutaneous adipose tissue
| Relative Change (%) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| Change in Body Weight and Body Composition (VAT/SAT Ratio) | -4.6 (-14.44 to 5.25) | -17.45 (-28.67 to -6.23) | 2.01 (-9.12 to 13.14) |
Collected over On or after the first dose of treatment up to 30 days post last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lanifibranor (800 mg/Day) | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | 0/13 (0%) | 1/13 (7.7%) | 9/13 (69.2%) |
| Placebo | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| Event | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| HaematuriaRenal and urinary disorders | 0/12 | 1/13 | 0/14 |
| Event | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 2/12 | 0/13 | 1/14 |
| HeadacheNervous system disorders | 2/12 | 1/13 | 0/14 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/12 | 0/13 | 0/14 |
| NauseaGastrointestinal disorders | 1/12 | 2/13 | 0/14 |
| OverdoseInjury, poisoning and procedural complications | 1/12 | 2/13 | 0/14 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/12 | 2/13 | 0/14 |
| RashSkin and subcutaneous tissue disorders | 0/12 | 0/13 | 2/14 |
| Ear pruritusEar and labyrinth disorders | 1/12 | 0/13 | 0/14 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/13 | 1/14 |
| ToothacheGastrointestinal disorders | 1/12 | 1/13 | 0/14 |
Thirty-nine (39) took at least 1 dose of treatment and were included in the Full Analysis Set (FAS) and were evaluable for safety (Safety Analysis Set SAS).
| Age, Categorical(Participants) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 10 | 10 | 29 |
| >=65 years | 3 | 3 | 4 | 10 |
| Age, Continuous(years) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.1 ± 11.45 | 54.2 ± 13.48 | 54.7 ± 13.01 | 54.6 ± 12.38 |
| Sex: Female, Male(Participants) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 8 | 7 | 21 |
| Male | 6 | 5 | 7 | 18 |
| Race (NIH/OMB)(Participants) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 3 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 10 | 10 | 9 | 29 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 7 | 18 |
| Not Hispanic or Latino | 5 | 9 | 7 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| HbA1c(Participants) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| <7.5% | 4 | 5 | 5 | 14 |
| ≥7.5% | 8 | 8 | 9 | 25 |
| Weight(Kg) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Mean | 93.30 ± 11.614 | 103.30 ± 12.437 | 94.50 ± 21.269 | 97.06 ± 16.213 |
| Height(cm) | Lanifibranor (800 mg/Day) | Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Mean | 167.08 ± 9.418 | 165.89 ± 8.911 | 164.73 ± 12.072 | 165.84 ± 10.077 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in May 2024, 22 months.
Results were first posted in Sep 2026, 2 years 4 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 22 months is close to that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lanifibranor
Non-alcoholic Fatty Liver Disease →
Inventiva Pharma